S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Buy THIS stock before Taiwan is attacked (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Buy THIS stock before Taiwan is attacked (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Buy THIS stock before Taiwan is attacked (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Buy THIS stock before Taiwan is attacked (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
NASDAQ:MEDP

Medpace - MEDP Stock Forecast, Price & News

$181.94
+1.42 (+0.79%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$175.38
$182.08
50-Day Range
$174.31
$239.52
52-Week Range
$126.94
$241.48
Volume
392,472 shs
Average Volume
391,015 shs
Market Capitalization
$5.65 billion
P/E Ratio
24.86
Dividend Yield
N/A
Price Target
$235.50

Medpace MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
29.4% Upside
$235.50 Price Target
Short Interest
Healthy
5.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.53mentions of Medpace in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.10%
From $7.66 to $8.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

44th out of 1,005 stocks

Commercial Physical Research Industry

4th out of 16 stocks


MEDP stock logo

About Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Stock News Headlines

Medpace (NASDAQ:MEDP) Lowered to "Hold" at StockNews.com
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Medpace Hldgs's Earnings: A Preview
Here’s Why Investors Hold Medpace Holdings (MEDP)
Medpace Holdings, Inc. (MEDP)
Why Medpace Holdings Jumped 41.5% This Week
Why Medpace Stock Soared Today
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Company Calendar

Last Earnings
2/13/2023
Today
3/25/2023
Next Earnings (Estimated)
4/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
5,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$235.50
High Stock Price Forecast
$238.00
Low Stock Price Forecast
$233.00
Forecasted Upside/Downside
+29.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$245.37 million
Pretax Margin
19.37%

Debt

Sales & Book Value

Annual Sales
$1.46 billion
Cash Flow
$8.74 per share
Book Value
$12.42 per share

Miscellaneous

Free Float
24,654,000
Market Cap
$5.65 billion
Optionable
Optionable
Beta
1.42

Key Executives

  • August James TroendleAugust James Troendle
    Chairman & Chief Executive Officer
  • Jesse J. GeigerJesse J. Geiger
    President
  • Susan E. Burwig
    Executive Vice President-Operations
  • Kevin M. BradyKevin M. Brady
    Chief Financial Officer & Treasurer
  • Brandon Ebken
    Chief Information Officer













MEDP Stock - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price objectives for Medpace's shares. Their MEDP share price forecasts range from $233.00 to $238.00. On average, they predict the company's share price to reach $235.50 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2023?

Medpace's stock was trading at $212.41 on January 1st, 2023. Since then, MEDP stock has decreased by 14.3% and is now trading at $181.94.
View the best growth stocks for 2023 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 24th 2023.
View our MEDP earnings forecast
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings results on Monday, February, 13th. The company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.78 by $0.34. The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $386.09 million. Medpace had a net margin of 16.81% and a trailing twelve-month return on equity of 60.42%. The company's quarterly revenue was up 27.7% on a year-over-year basis. During the same period last year, the firm earned $1.32 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided EPS guidance of $7.53-$8.14 for the period, compared to the consensus EPS estimate of $7.72. The company issued revenue guidance of $1.69 billion-$1.75 billion, compared to the consensus revenue estimate of $1.70 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fuller & Thaler Asset Management Inc. (3.02%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.88%), Boston Trust Walden Corp (1.76%), Riverbridge Partners LLC (1.47%) and Millennium Management LLC (1.45%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $181.94.

How much money does Medpace make?

Medpace (NASDAQ:MEDP) has a market capitalization of $5.65 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $7.32 on an earnings per share basis.

How many employees does Medpace have?

The company employs 5,200 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.

This page (NASDAQ:MEDP) was last updated on 3/26/2023 by MarketBeat.com Staff